RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the ...

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested Nvidia earnings and Trump's latest tariff threats.

US stocks fell after Nvidia fails to wow investors. Trump's tariff talk also adds jitters. Inflation data due Friday.

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Nvidia is helping to prop up the U.S. stock market, and indexes are drifting higher. The S&P 500 rose 0.4% in early Thursday ...

Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...